

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 July 2021 (15.07.2021)



(10) International Publication Number
WO 2021/140202 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 31/573 (2006.01)
A61P 17/00 (2006.01) A61P 37/06 (2006.01)

(21) International Application Number:

PCT/EP2021/050275

(22) International Filing Date:

08 January 2021 (08.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/958,543 08 January 2020 (08.01.2020) US
62/960,647 13 January 2020 (13.01.2020) US

(71) Applicant: **ARGENX BV** [BE/BE]; Industriepark Zwi-
naarde 7, 9052 Gent (BE).

(72) Inventors: **VERHEESEN, Peter**; c/o Industriepark Zwi-
jnaarde 7, 9052 Gent (BE). **DUPUY, Patrick**; c/o Indus-
triemark Zwijsnaarde 7, 9052 Gent (BE).

(74) Agent: **BOULT WADE TENNANT LLP**; Salisbury
Square House, 8 Salisbury Square, London Greater London
EC4Y 8AP (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS FOR TREATING PEMPHIGUS DISORDERS

	Cohort 1 6	Cohort 2 5	Cohort 3 8	Cohort 4 15
Eligibility criteria	10			25
Induction	4 Weekly infusions			Weekly infusions until EoC
Maintenance period (weeks)	6	8	12	Up to 34
Maintenance dosing	2 doses at weeks 2 and 6			Every other week
Allocated prednisone	No steroids or stable dose of prednisone (patients relapsing on therapy)			Discretion of investigator (monotherapy or 20 mg/d) 20 mg/d (patients off therapy) or stable dose (patients on therapy)

Fig. 1

(57) Abstract: Provided are methods for treating pemphigus using an FcRn antagonist such as efgartigimod. The methods of the invention provide a rapid onset of action to enable early disease control and maintenance of clinical remission, with or without a minimal dose of corticosteroids.

WO 2021/140202 A1